Supporting Information

Quenched cetuximab conjugate for fast fluorescence imaging of EGFRpositive lung cancers

Hyunjin Kim^a, Sung-Ho Goh*,^b, and Yongdoo Choi*,^a

Research Institute, National Cancer Center, 323 Ilsan-ro, Goyang, Gyeonggi 10408, Republic of Korea



Figure S1. Analysis of the fluorescence intensity across the area indicated by the white lines in A549-Luc2 cells after treatment for 1 h. Green colored lines indicate the fluorescence signals of LysoTracker (λ_{ex} 405 nm, λ_{em} 420-480 nm) and red colored lines indicate the fluorescence signals of Q-Cetuximab (λ_{ex} 633 nm, λ_{em} 647-754 nm). Scale bar = 20 μ m.



Figure S2. Time lapse images of Q-Cetuximab in A549-Luc2 cells. Q-Cetuximab (2 μ M) was added and images were captured every 1 h for 24 h without washing the cells (λ_{ex} 633 nm, λ_{em} 638-759 nm).



Figure S3. Bioluminescence images of A549-Luc2-injected mice. A549-Luc2 cells (5×10^6 cells/25 µL) mixed with Matrigel (25μ L) were injected into the right lateral thorax. For bioluminescence imaging of the mice, luciferin ($2 \text{ mg} / 100 \mu$ L PBS) was intravenously injected via the tail vein, and bioluminescence images were obtained 10 min post-injection.